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INTRODUCTION
Regulation of the level of apoptosis in
hemopoiesis could potentially provide a
mechanism for regulating stem and prog-
enitor cell population size. Thus, if there is
substantial overproduction of stem or
progenitor cells and compensatory loss by
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Objectives: CD34+ cells and colony forming unit-granulocyte and macrophage (CFU-GM)
from human bone marrow were used to investigate the role of Fas/FasL system in the reg-
ulation of myelopoiesis. Methods: Fas and FasL expression in CD34+ cells and in day 14
CFU-GM were measured by RT-PCR and immunofluorescence respectively. The function-
al assays for the CFU-GM were measured by a standard colony assay and the prolifera-
tive capacity of CFU-GM was measured by replating the primary colony and observing the
secondary colony formation. Human marrow cells were treated with IETD (caspase-8
inhibitor) or anti-Fas CH-11 Mab. Results: Treatment with the CFU-GM with IETD signifi-
cantly increased, the proliferative capacity, while anti-Fas CH-11 Mab markedly reduced it.
Fas and FasL expression were demonstrated using RT-PCR and immunofluorescence
respectively. Conclusion: Fas, FasL, and caspase activation are likely to play an important
role in the regulation of myelopoiesis.apoptosis during normal hemopoiesis, it
would be possible to increase mature cell
production in response to demand (e.g.,
anemia, neutropenia), by reducing the
level of apoptotic cell loss. It would be
also be possible for dysregulation of apop-
tosis to lead to leukemia.
One of the best characterized apoptot-
ic signalling cascades follows the engage-
ment of FasR/CD95 with its ligand
FasL/CD95L [1-5]. FasR (CD95) is a 48
kDa cysteine rich type I cell membrane
protein, a member of the TNF/NGF recep-
tor gene family which also includes
TNFR, DR3, DR4, DR5, DR6 andAPRIL.
FasR is broadly expressed on a vari-
ety of cells including liver, lung, intestine,
heart, kidney, ovary, various lymphomas,
and leukemic cells [6-8]. In contrast, the
expression of Fas ligand (FasL)† appears
to be more restricted to natural killer (NK)
cells, cytotoxic T lymphocytes (CTL) [9],
and cells in immunoprivileged sites such
as the eye [10].
FasR, TNFR1 and other family mem-
bers bear in their cytoplasmic domain
motifs known as death domains (DD),
which associate with each other to form
trimers following ligation with their corre-
sponding ligands.This association seems to
be the first step in signal transduction. The
aggregated DD of FasR recruits the DD on
the adaptor protein Fas-associated death
domain (FADD). In the TNFR pathway, an
intermediate molecule “TNFR-associated
death domain” (TRADD) interacts with
FADD. Together, Fas and FADD form a
death-inducing signalling complex (DISC)
with FADD like ICE (FLICE)/caspase-8.
The N-terminal end of FLICE consists of
two death effector domains (DED) [11-12].
ActivationofDEDleadstotheactivationof
terminal caspases-3, -6 and -7, and subse-
quently to degradation of lamin, actin, and
polyADP-ribose polymerase (PARP).
Most publications on the subject show
that the anti-Fas Mab CH-11 induces
apoptosis by activating the Fas pathway
[13-14]. Consequently, CH-11 might be
expected to reduce proliferation by colony
forming unit-granulocyte and macrophage
(CFU-GM). However, a study by Barcena
and colleagues reported that the anti-Fas
CH-11 Mab induced a dose-dependent
proliferative response by CD34+CD38-
cells and significantly increased the num-
ber of CFU-GM colonies generated by
hemopoietic stem cell (HSC) in liquid cul-
ture [15]. This observation might suggest
that in some circumstances CH-11 blocks
Fas. Similarly, sFasL was found to
enhance the generation of cells of the ery-
throid and granulocytic lineages and also
to increase the viability of CD34+CD38-
cells [16]. Therefore, their results indicate
that Fas/FasL system may regulate human
hemopoietic progenitor cells in a way that
is closely similar to the mechanism sug-
gested by Alenzi et al. [17] for murine
progenitor cells.
Other evidence also supports the
involvement of Fas and FasL in regulating
hemopoiesis. Peschle’s group [18] has
demonstrated the possible involvement of
Fas and FasL in the regulation of erythro-
poiesis by immunohistochemistry of nor-
mal bone marrow samples, which revealed
that immature erythroblasts undergo apop-
tosis in vivo. These findings suggest the
existence of a negative regulatory feed-
back between mature and immature ery-
throid cells.Accordingly, the interaction of
Fas and FasL might represent an apoptotic
control mechanism for erythropoiesis,
contributing to the regulation of red blood
cell homeostasis. Traver et al. [19] pro-
posed that granulopoiesis could be regu-
lated similarly by a negative feedback
mechanism through interactions between
Fas-expressing clonogenic cells and neu-
trophils that express FasL.
Caspase-8 inhibitor (IETD) was
added to the CFU-GM cultures. It is
involved in the induction of apoptosis and
has been considered to be correlated with
apoptosis because of the most downstream
enzyme in their apoptosis-inducing path-
way. IETD was used to inhibit apoptosis
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blocks caspase activation.
The work described in this study was
directed toward determining whether
apoptosis mediated by Fas and FasL influ-
ences progenitor cell kinetics as reflected
in the AUC assay, i.e., proliferation in
humans. There is evidence in the literature
that Fas and FasL influence human hemo-
poietic progenitor cell numbers in differ-
ent in vitro systems, but their affects on
human progenitor cell proliferation kinet-
ics have not been investigated before.
The purpose of this study was to
address the question of whether the
Fas/FasLsystem is likely to be involved in
the regulation of myeloid progenitor cell
population size in human model. First, a
role for apoptosis was investigated by
exposing normal bone marrow (NBM)
CFU-GM to IETD. Second, the plating
efficiency of CFU-GM and its prolifera-
tive capacity was determined after being
exposed to anti-Fas Mab CH-11. Thirdly,
the expression of Fas and FasL in human
CD34+ cells and CFU-GM respectively
was investigated. For this, CD34+ cells




NBM samples were obtained from
individuals donating cells for allogeneic
transplantation. Written informed consent
and Research Ethics Committee approval
were obtained in all cases. Mononuclear
cells (MNCs) were obtained by density gra-
dient centrifugation over Ficoll-Hypaque
(1.077 g/ml) (Nyegaard, Oslo, Norway).
After washing with HBSS (GibcoBRL,
Carlsbad, California, United States), cells
were resuspended in HBSS. To calculate the
concentration of nucleated cells, the sample
was diluted with 3 percent acetic acid to
lyse red blood cells, and an aliquot placed in
a hemocytometer counting chamber. The
cell concentration was adjusted to 10 x
106/5 ml with 15 percent FCS in minimal
essential medium (MEM) (GibcoBRL). The
cell suspension was placed in a 25 cm2 plas-
tic flask for two-hour incubation at 37oC in
humidified 5 percent CO2 in air to remove
adherent monocytes and macrophages. Non
adherent MNCs were harvested for culture.
Sources of recombinant cytokines
and growth factors
Recombinant human granulocyte-
colony stimulating factor (G-CSF; 100
ng/ml), granulocyte-macrophage-colony
stimulating factor (GM-CSF; 10 ng/ml),
interleukin-3 (IL-3; 25 ng/ml), and stem
cell factor (SCF;100 ng/ml). All recombi-
nant cytokines were obtained from First
Link (West Midlands, United Kingdom).
The concentration of each cytokine used
was optimized in the laboratory.
Reagents
IETD (Bachem, United Kingdom) was
used at 10 M; anti-Fas Mab CH-11 was
purchased from Upstate Biotechnology
(Lake Placid, New York); anti-FasL Mab
(65321A) was purchased from PharMingen
(San Diego, California, United States),
sFasL was purchased from Alexis (San
Diego, California, United States); Blocking
anti-Fas Mab ZB4 from MBL was used at
1 ng/ml (Nagoya, Japan); and irrelevant
IgG1 control Mab (PharMingen) served as
isotype-matched control.
Clonogenic CFU-GM assay
Non-adherent MNCs were mixed with 3
ml of methylcellulose (MC) (1 x 105 cells/ml)
(StemCell Technologies, Grenoble, France)
containing 10 percent FCS and supplemented
with recombinant human cytokines (IL-3 [5
ng/ml] and SCF [20 ng/ml]). After being
mixed well, 1 ml aliquots were plated out
into three 35 cm2 diameter petri dishes. The
dishes were then incubated at 37oC in humid-
ified 5 percent CO2 in air for seven days.
Colonies consisting of 50 cells or more were
scored under an inverted microscope, and
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GM per 105 cells.
Purification of human CD34+ cells
CD34+ cells were separated using
MiniMACS magnetic immuno-affinity
columns as directed by the manufacturer
(Milteny Biotec, Auburn, California).
Cells from pooled day 7 CFU-GM were
incubated for 15 min at 4oC with 100 ﾵl
reagent A1 (blocking FcR), 100 ﾵl of
reagentA2 (hapten-conjugated anti CD34+
Mab), and 300 ﾵl of MiniMacs buffer
(MM) containing calcium and magne-
sium-free PBS (GibcoBRL), 0.5 percent
human serum albumin (ImmunoAG), and
5 mM EDTA (GibcoBRL). Following a
single wash in 10 ml MM, cells were
resuspended with 100 ﾵl reagent B (anti-
hapten Mab conjugated to beads) and 400
ﾵl of MM buffer and incubated for 15 min-
utes at 4oC. Cells then were washed again
in 10 ml MM and gently but thoroughly
resuspended in 1 ml of MM buffer. The
labeled cells were loaded onto the affinity
column held in a magnet and CD34+ cells
washed through with 4 x 0.5 ml of MM
buffer.After removal from the magnet, the
CD34+ cells were vigorously expelled
from the column with 1 ml MM buffer.
The purity is about 85 percent to 98 per-
cent, confirmed by flow cytometry.
CFU-GM replating assay
After seven days of incubation, 120
colonies consisting of 50 cells or more
were plucked individually from methycel-
lulose using a sterile eppendorf pipette and
thoroughly dispersed in separate wells of a
96-well plate, each containing 100 ﾵl of
MC plus FCS and supplemented with IL-3
(5 ng/ml), G-CSF (100 ng/ml), GM-CSF
(1 ng/ml), and SCF (20 ng/ml). The sur-
rounding wells were filled with sterile
water to prevent evaporation during incu-
bation. Plates were incubated for a further
seven days at 37oC in humidified 5 percent
CO2 in air. Then each well was scored for
secondary colonies of more than 50 cells.
The results were plotted as the
cumulative distribution of the proportion
of primary CFU-GM producing more
than (n) secondary colonies. Both axes
are expressed on a logarithmic scale.
This step allows good data fit, so the area
under the curve (AUC) can be measured
using the Trapezium Rule using
Microsoft Excel version 5.0 on a
Macintosh computer. The AUC is mea-
sured because the distribution of sec-
ondary colonies is highly skewed rather
than being normally distributed.
Therefore, the median and not the mean
is the correct value to use. However, for
cases where more than 50 percent of the
replated colonies do not yield secondary
colonies, the median would be zero and
uninformative.
TheAUC is calculated to provide an
overall measure of progenitor cell self-
renewal capacity and is particularly use-
ful in situations where this capacity is
suppressed.
Detection of Fas by reverse transcrip-
tion-polymerase chain reaction (RT-
PCR)
Total RNA was isolated from a con-
stant number of CD34+ cells-derived
CFU-GM at day seven of incubation using
a Qiagen gel purification kit, according to
the manufacturer’s instructions. First-
strand cDNAsynthesis and PCR were per-
formed. For the amplification, PCR
primers were used (see below).
Fas R: 5'-CAA GTC CAA CTC AAG
GTC CAT GCC-3' (bases no. 517-540).
Fas F: 5'-CAG AGA GAG CTC AGA
TAC GTT GAC-3' (bases no. 839-862).
Thirty-five cycles of PCR, with denat-
uration at 94oC for 30 seconds, annealing
at 60oC for 1 minute, and extension at
72oC for 1 minute, were performed on a
programmed-temperature system (Hybaid
OmniGene; Midwest Scientific, Missouri,
United States).
After PCR amplification, 10 ﾵl of the
PCR products were mixed with 2 ﾵl of 6X
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mophenol blue, 40 percent w/v sucrose in
water) and electrophoresed on a 2 percent
agarose gel containing 0.2 ﾵg/ml ethidium
bromide in 0.5X TBE buffer. A DNA lad-
der was also run in parallel. The amplified
gel was visualized and photographed
under UV light.
Detection of FasL by direct
immunofluorescence
Direct immunofluorescence was used
to confirm the presence of FasL. 105 cells
were deposited on slides using a cytocen-
trifuge and stained with an anti-FasLFITC
conjugate (PharMingen). The cells were
incubated with the antibody at 1:100 dilu-
tion at RT for 1 hour.
Slides were washed three times with
PBS for 5 minutes, mounted with glycerol
mountant and checked under an Olympus
fluorescence microscope. Matched isotype
antibody control was used at 1:100 at RT
for 1 hour.
Statistical analysis
Statistical analysis was carried out
using Microsoft Excel spreadsheet and the
StatView SE+ graphics software. The
probability of a significant difference
between groups was determined by
Wilcoxon signed rank test.
Graphs were plotted using the Cricket
Graph graphics package. The AUC was
calculated using a Microsoft Excel
spreadsheet. All software was run on a
Macintosh computer.
RESULTS
Effect of IETD on CFU-GM plating
efficiency in methylcellulose cultures
To determine whether caspases could
play a role in the terminal myeloid differen-
tiation, we used a human bone marrow-
derived CFU-GMs grown in the presence
of IETD for 7 days. As may be seen from
Figure 1, IETD significantly increased the
AUC. However, the 1.6-fold increase was
less marked than the 2.5-fold increase in
WT mouse cultures [17]. This result indi-
cates that apoptosis may play a role in reg-
ulating hemopoietic progenitor cell kinetics
in humans as it does in mice. This observa-
tion suggested also that caspase activation
was required for the myeloid maturation.
Expression of Fas on CD34+
cells-derived day 7 CFU-GM
We determined whether Fas is
expressed in CD34+ cells-derived day 7
CFU-GM by RT-PCR. Fas was detected in
almost all obtained CD34+ cells (Figure 2).
Expression of FasL on day 14
CFU-GM
Experiments were performed first to
demonstrate that FasL was present in day
14 CFU-GM cells. To investigate the
expression of FasLprotein in day 14 CFU-
GM, they were deposited on slides using a
cytocentrifuge and stained with an anti-
FasL FITC conjugate (PharMingen). The
cells were incubated with the antibody.
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Figure 1. Effect of IETD (10
M) on self-renewal capaci-
ty, as measured by the
AUC, of CFU-GM derived
from human BM cells.
Results are expressed as
percentage of the control
(line shown at 1.0 level).
There is a significant differ-
ence between NBM treated
with IETD and untreated
controls (Wilcoxon signed-
rank test).Approximately 90 percent of day 14 CFU-
GM expressed FasL(Figure 3). To exclude
any interference, normal FITC-IgG was
set as a control (data not shown).
Demonstration of functional Fas
Barcena et al. and others [15-16]
reported that the anti-Fas Mab CH-11 sig-
nificantly increases the number of CFU-
GM colonies generated from HSC in liq-
uid culture in a dose-dependent manner
over a range of 1 to 10 ﾵg/ml. Therefore,
this Mab CH-11 was used to investigate
whether the effects of IETD (Figure 1)
could be related to the Fas/FasL pathway.
To assess the effect of Mab CH-11 on
cell death, 106 Jurkat T cells were incubat-
ed with anti-Fas Mab CH-11 at 1 ﾵg/ml
and 0.1 ﾵg/ml. The percentage of apoptot-
ic cells was calculated using the trypan
blue dye-exclusion test (> 40 percent in 3
days). As a positive control, the effects of
1 ﾵg/ml anti-Fas CH-11 Mab on Jurkat
cells were examined. This result identified
CH-11 as an effective pro-apoptotic
reagent in the Jurkat cell line model (data
not shown).
When CH-11 was added to clono-
genic cultures in methycellulose, there
was a trend effect on the CFU-GM plating
efficiency at 10 ﾵg/ml (Figure 4).
Therefore, CH-11 does not appear to have
any significant cytotoxic or stimulatory
effects on primary colony formation when
the cells are plated into methylcellulose
straight away. Additionally, the results in
Table 1 shows that there are differences
with regard to the composition, i.e., cell
number of day seven and day 14 colonies,
between treated and non-treated cells in
the presence of ascending concentrations
of anti-Fas Mab.
The influence of CH-11 on prolifera-
tion (the AUC) by CFU-GM grown in its
presence was then investigated. At 10
g/ml, CH-11 significantly reduced the
replating ability (AUC) by 30 percent to
0.71 ﾱ 0.1 (m ﾱ se) of the control values.
Neither 1 ﾵg/ml nor 0.1 ﾵg/ml had any sig-
nificant effect. The lower dose of anti-Fas
Mab 0.01 g/ml, significantly increased the
replating ability (AUC) (p = .02) (Figure
5). This result suggests that CH-11 may
have a biphasic effect on progenitor cell
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Figure 2. Expression of Fas into CD34+-cells-derived CFU-GM was determined by
RT-PCR. Ten day 7 CFU-GM colonies were collected and tested by PCR. Ten colonies
were PCR-positive.
Figure 3. Immunofluorescence staining showing the FasL expression on day 14
CFU-GM, when stained with anti-FasL FITC Mab, compared to cells stained with iso-
type control (not shown). Data are a representative of four experiments.proliferation. The stimulatory effect was,
however, observed only at very low anti-
body concentration. It is noteworthy that
no stimulation of primary CFU-GM plat-
ing efficiency was seen at this concentra-
tion (see Figure 4). The inhibitory effect
seen at 10 ﾵg/ml is consistent with a pro-
apoptotic effect of CH-11 and a role for
Fas in regulating human hemopoiesis.
Our results suggest that CH-11 is
functioning to block FasL interaction with
Fas. This suggestion has been confirmed
using commercial blocking anti-Fas ZB4
Mab to Fas (Figure 6). The biphasic
response to CH-11 is interesting, therefore
it was of importance to validate this by
incubating CD-34 cells with CH-11 at the
various concentrations in liquid culture and
measuring apoptosis (Figure 7). sFasL was
utilized as a positive control (Figure 8).
DISCUSSION
The regulation of hemopoietic stem
and progenitor cell numbers involves the
balance between proliferation, differentia-
tion, and apoptosis [20]. Thus, two main
mechanisms may account for an increase
in hemopoietic stem/progenitor cell num-
bers. The first, a reduction in progenitor
cell loss by apoptosis, supposes that sub-
stantial numbers of them are lost by apop-
tosis in steady-state hemopoiesis [21]. The
second is an increase in progenitor cell
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Figure 4. Number of CFU-
GM colonies grown in the
presence of anti-Fas Mab.
There is a no significant differ-
ence between the controls
and anti-Fas Mab-containing
plates (Wilcoxon Signed-rank
test). Results are expressed
as percentage of the control.
Table 1. Number of CFU-GM colony-forming cells in methylcellulose cultures con-
taining CH-11 at escalating concentrations. CFU-GM were assayed prior to and after 7
and 14 days of culture. There was a dramatic elevation in numbers of CFU-GM after 14
days exposure to 10 ﾵg/ml, 1 ﾵg/ml, 0.1 ﾵg/ml, and 0.01 ﾵg/ml, CH-11 Mab compared to
numbers of CFU-GM at day 7.proliferation at the expense of differentia-
tion. Until recently, studies on the involve-
ment of Fas and FasL in hemopoiesis have
focused on their proapoptotic functions
[22-25]. However some reports indicated
that activation of downstream caspases
can exert regulatory effects in the absence
of cell death [26]. This led us to investi-
gate the influence of Fas and FasL on the
regulation of myelopoiesis. We evaluated
the influence of the Fas and FasL apoptot-
ic pathway on myeloid progenitors in pri-
mary and secondary CFU-GM obtained
from normal human bone marrow. We
investigated the hypothesis that Fas and
FasL and downstream caspase activity
play a role in regulating myeloid progeni-
tors proliferation and differentiation.
IETD is a specific inhibitor of cas-
pase-8. The finding that IETD significant-
ly increased the AUC to the controls, but
its effect on human cells was less marked
than its effect on murine cells [17]. It is of
relevance and interest that caspase-1 has
been shown to participate in cleaving pRb
[27-29], which is involved in regulating
progenitor cell proliferation, differentia-
tion, and hemopoiesis [30-31]. More inter-
estingly, caspase-3 has been shown to be
associated with altered expression of
cyclin-dependent kinase inhibitors: p16,
p21, and p27 [32-33], which also influence
progenitor cell proliferation and differenti-
ation [34].
Fas and FasLare a very important cel-
lular pathways responsible for initiation of
apoptosis. Fas is 45 kDa membrane glyco-
protein and is widely distributed; in con-
trast, FasL is 40 kDa and is relatively
restricted to some tissues. We studied the
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Figure 5. Self-renewal
capacity (AUC) of CH-
11-treated colonies.
There is a significant
increase in the AUC at
0.01 g/ml and a signifi-
cant decrease at 10




capacity (AUC) of CFU-GM
from NBM grown in the pres-
ence of 0.01 g/ml anti-Fas
CH-11 Mab. There is a signifi-
cant decrease in the AUC
when anti-Fas blocking Mab
ZB4 was added, compared to
colonies treated with CH-11
(Wilcoxon signed-rank test).expression of both Fas and FasL in CD34+
cells and in day 14 CFU-GM using RT-
PCR and direct immunofluorescence
respectively.
To investigate whether the Fas Mab
CH-11 modulates proliferation of CFU-
GM cells in NBM, we have used a com-
mercially available Fas Mab CH-11. This
reagent has been used by two other groups
[15-16] who showed that it stimulated
human hemopoietic progenitor cell prolif-
eration although it is generally accepted
that Fas ligation often leads to massive
apoptosis in Fas-expressing cells [13-14].
Ligation of Fas with CH-11 Mab marked-
ly reduced the AUC, indicating that Fas
expression was associated with functional
inhibition of CFU-GM. Therefore, these
observations suggest that the Fas/FasL
system is responsible for at least part of
the inhibition of myelopoiesis in human
CFU-GM.
Primary CFU-GM(s) were grown in
the presence of CH-11, then replated for
secondary colonies. CH-11 had no affect on
primary CFU-GM. In the replating assay,
CH-11 had a biphasic effect. Increased pro-
liferation of progenitor cells was observed
at the lowest concentration used 0.01 ﾵg/ml
anti-Fas CH-11 Mab in methylcellulose
culture. It is possible, therefore, that anti-
Fas Mab suppresses proliferation at higher
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Figure 7. One million CD34+
cells were incubated with
descending concentrations of
human anti-Fas CH-11 Mab.
The percentage of non-viable
cells was scored using the trypan
blue dye-exclusion test. The fig-
ure shows that CH-11 is a strong
inducer of cell death.
Figure 8. One million CD34+
cells were incubated with
sFasL at 100 ng/ml for 6
hours, 1 day, and 2 days. The
percentage of non-viable cells
was scored using the trypan blue
dye-exclusion test. The results
showed that sFasL induced cell
death significantly to the level of
the control.concentrations,probablyduetoanabilityto
mimic apoptotic downstream signals. In
contrast, at lower concentrations, it may
block access of FasL to Fas and lead to a
proliferative effect.
Also, since Fas is a multifunctional
protein belonging to the TNF superfamily,
it can trigger and activate two separate
pathways. Fas binds to FADD death
domains, leading to recruitment of cas-
pase-8, which eventually leads to apopto-
sis. It should be noted, however, that 0.01
g/ml is much lower than the lowest con-
centration used by Barcena et al. when
they demonstrated a proliferative effective
of CH-11. Although the exact role of
NFκB in apoptosis is not fully understood,
two pieces of evidence demonstrated that
NFκB activation can inhibit apoptosis in
neuron cells [35] and non-neurons cells
[36]. Chu et al. [37] demonstrated that
TNF-receptor-associated protein 2
(TRAF2) interacts with the inhibitors of
apoptosis proteins (IAP), which have been
shown to increase the levels of NFκB.
Other evidence is provided by Ravi et al
[38] who demonstrated that NFκB was
activated by Fas. The former evidence
suggests that IAP could abolish apoptosis
directly by inhibiting caspase activation,
or alternatively via increased activation of
NFκB.
The results reported in this study do
not support the findings of Barcena et al.
or Josefsen et al. because no convincing
proliferative effect of CH-11 was found in
any of the progenitor cell culture systems
tested [15-16]. This may not be surprising
in view of the fact that CH-11 was identi-
fied as an effective pro-apoptotic reagent
in the Jurkat cell line model. However,
CH-11 did not have any striking effects on
progenitor cells that would be consistent
with a pro-apoptotic effect either, with the
exception of its negative influence on the
replating ability of CFU-GM (Figure 5).
Importantly, the 30 percent reduction in
AUC shown in Figure 3 is consistent with
the increase in AUC seen in the presence
of IETD (Figure 1). Additionally, most of
CFU-GM in our cultures at day 14 are
FasL+ cells.
Our results are contradicted by Kim et
al. [39] who demonstrated that CD34+
cells do not express Fas and that they are
resistant to anti-Fas Mab and sFasL-
induced apoptosis. Moreover, they showed
that CD34+ cells express FLIP which pro-
tects from Fas-mediated apoptosis. Upon
GM-CSF deprivation or Fas activation,
caspase activity is amplified via either the
caspase-9 pathway or the caspase-8 path-
way, respectively, which leads eventually
to apoptosis. Therefore, in this study, we
have described a new function for caspas-
es as regulators for myeloid proliferation.
Overall, our results suggest that the
Fas/FasL pathway and caspase activation
inhibit cell proliferation and promote dif-
ferentiation. Therefore, our results support
the previous proposals that the caspase
activation may have nonapoptotic func-
tions in the regulation of hemopoiesis [26].
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